NASDAQ$COGT
Cogent Biosciences Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023.
Cogent Biosciences reported a net loss of $44.1 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $350.9 million, expected to fund operations into 2026. They presented positive data from the lead-in portion of Phase 3 PEAK study and selected FGFR2 clinical candidate.
- Presented positive lead-in data from the ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors (GIST) at the 2023 ASCO annual meeting.
- Selected a potent, selective, reversible FGFR2 kinase inhibitor as the first internally developed clinical candidate from the Cogent Research Team.
- Closed an underwritten public offering of 14,375,000 shares of common stock at a public offering price of $12.00 per share, receiving net proceeds of approximately $161.8 million.
- Cash, cash equivalents and marketable securities were $350.9 million, sufficient to fund operations into 2026.
Headline financials
Revenue & EPS history
Cogent Biosciences · Revenue · Quarterly
$0
Forward guidance
Cogent plans to present initial clinical data from SUMMIT and updated clinical data from APEX in the second half of 2023. They also plan to present additional preclinical data on its FGFR2 candidate in the second half of 2023 and to initiate clinical trials in 2024. The company anticipates its cash runway into 2026 and plans to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in September 2023.
Tailwinds
- Present initial clinical data from SUMMIT in the second half of 2023.
- Present updated clinical data from APEX in the second half of 2023.
- Present additional preclinical data on its FGFR2 candidate in the second half of 2023.
- Initiate clinical trials for FGFR2 candidate in 2024.
- Participate in the Morgan Stanley 21st Annual Global Healthcare Conference in September 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.9%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.5%
Avg return
30 days after
65%
20 / 31 earnings
Positive
+17.8%
Q3 2018
Best reaction
-24.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -5.3% | -10.6% | |
| Q3 2025 | -4.4% | -9.1% | +140.2% | |
| Q2 2025 | -5.8% | -9.0% | +7.4% | |
| Q1 2025 | +2.7% | +4.4% | +48.4% | |
| Q4 2024 | -6.3% | +0.9% | -11.4% | |
| Q3 2024 | +0.0% | -14.4% | -19.8% | |
| Q1 2024 | +0.4% | -0.1% | +11.1% | |
| Q4 2023 | +0.7% | -2.8% | -12.4% | |
| Q3 2023 | +3.9% | +3.8% | -2.7% | |
| Q2 2023 | +7.3% | +8.8% | +9.4% | |
| Q1 2023 | -1.5% | -2.6% | -2.9% | |
| Q4 2022 | +0.7% | -5.1% | -13.7% | |
| Q3 2022 | -5.7% | -8.5% | -2.6% | |
| Q2 2022 | +9.6% | +12.1% | +32.7% | |
| Q1 2022 | -24.0% | -26.8% | -10.6% | |
| Q4 2021 | +4.5% | +28.4% | +64.6% | |
| Q3 2021 | +13.7% | +12.1% | -9.9% | |
| Q2 2021 | +5.4% | +13.4% | +3.3% | |
| Q1 2021 | +1.7% | +4.9% | +4.0% | |
| Q4 2020 | +5.9% | +5.5% | +9.0% | |
| Q3 2020 | +13.2% | +9.8% | +14.9% | |
| Q2 2020 | -11.4% | -11.0% | -8.3% | |
| Q1 2020 | +0.5% | +17.9% | +37.1% | |
| Q4 2019 | -3.1% | -15.5% | -18.6% | |
| Q3 2019 | -10.2% | -32.6% | -52.1% | |
| Q2 2019 | +4.4% | +9.3% | +9.0% | |
| Q1 2019 | +0.2% | -1.1% | -26.2% | |
| Q4 2018 | +8.1% | +5.4% | -12.3% | |
| Q3 2018 | +17.8% | +18.5% | -25.0% | |
| Q2 2018 | -5.9% | -12.8% | -27.3% | |
| Q1 2018 | +4.0% | +12.4% | +13.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro